Core Scientific Tranche Stock Performance
| CORZZ Stock | 18.65 0.65 3.61% |
The firm shows a Beta (market volatility) of 1.39, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Core Scientific will likely underperform. At this point, Core Scientific Tranche has a negative expected return of -0.018%. Please make sure to confirm Core Scientific's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to decide if Core Scientific Tranche performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Core Scientific Tranche has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Core Scientific is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 3.61 | Five Day Return 4.31 | Year To Date Return 17.07 | Ten Year Return 1 K | All Time Return 1 K |
1 | Acquisition by Weiss Eric Stanton of 5000 shares of Core Scientific, at 21.5 subject to Rule 16b-3 | 11/04/2025 |
2 | Acquisition by Rozov Yadin of 30000 shares of Core Scientific, at 6.81 subject to Rule 16b-3 | 11/12/2025 |
3 | and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com | 12/03/2025 |
4 | Acquisition by Levitt Michael J of 85355 shares of Core Scientific, subject to Rule 16b-3 | 12/05/2025 |
5 | Disposition of 20000 shares by Todd DuChene of Core Scientific, at 6.81 subject to Rule 16b-3 | 12/09/2025 |
6 | Disposition of 40100 shares by Rozov Yadin of Core Scientific subject to Rule 16b-3 | 12/30/2025 |
7 | Disposition of 139873 shares by Todd DuChene of Core Scientific at 15.08 subject to Rule 16b-3 | 12/31/2025 |
| Begin Period Cash Flow | 69.7 M | |
| Total Cashflows From Investing Activities | -95.2 M |
Core Scientific Relative Risk vs. Return Landscape
If you would invest 1,983 in Core Scientific Tranche on October 26, 2025 and sell it today you would lose (118.00) from holding Core Scientific Tranche or give up 5.95% of portfolio value over 90 days. Core Scientific Tranche is currently producing negative expected returns and takes up 4.0873% volatility of returns over 90 trading days. Put another way, 36% of traded stocks are less volatile than Core, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Core Scientific Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Core Scientific's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Core Scientific Tranche, and traders can use it to determine the average amount a Core Scientific's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Core Scientific is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Core Scientific by adding Core Scientific to a well-diversified portfolio.
Core Scientific Fundamentals Growth
Core Stock prices reflect investors' perceptions of the future prospects and financial health of Core Scientific, and Core Scientific fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Core Stock performance.
| Return On Asset | -0.0606 | |||
| Profit Margin | (2.30) % | |||
| Operating Margin | (0.60) % | |||
| Revenue | 510.67 M | |||
| Gross Profit | 34.13 M | |||
| EBITDA | (1.16 B) | |||
| Net Income | (1.32 B) | |||
| Total Debt | 1.2 B | |||
| Book Value Per Share | (3.66) X | |||
| Cash Flow From Operations | 42.9 M | |||
| Total Asset | 1.6 B | |||
| Retained Earnings | (3.74 B) | |||
| Working Capital | 769.4 M | |||
About Core Scientific Performance
Evaluating Core Scientific's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Core Scientific has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Core Scientific has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.95) | (0.99) | |
| Return On Capital Employed | (0.02) | (0.02) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | 1.44 | 0.95 |
Things to note about Core Scientific Tranche performance evaluation
Checking the ongoing alerts about Core Scientific for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Core Scientific Tranche help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Core Scientific generated a negative expected return over the last 90 days | |
| Core Scientific has high historical volatility and very poor performance | |
| Core Scientific has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 510.67 M. Net Loss for the year was (1.32 B) with profit before overhead, payroll, taxes, and interest of 34.13 M. | |
| Latest headline from MacroaxisInsider: Disposition of 139873 shares by Todd DuChene of Core Scientific at 15.08 subject to Rule 16b-3 |
- Analyzing Core Scientific's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Core Scientific's stock is overvalued or undervalued compared to its peers.
- Examining Core Scientific's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Core Scientific's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Core Scientific's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Core Scientific's stock. These opinions can provide insight into Core Scientific's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Core Stock Analysis
When running Core Scientific's price analysis, check to measure Core Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Scientific is operating at the current time. Most of Core Scientific's value examination focuses on studying past and present price action to predict the probability of Core Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Scientific's price. Additionally, you may evaluate how the addition of Core Scientific to your portfolios can decrease your overall portfolio volatility.